Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Current and Projected Market Size of the Emphysema Market Through 2034?
In recent times, the market size of emphysema has seen stable growth. It is expected to expand from $4.74 billion in 2024 to $4.94 billion in 2025, marking a compound annual growth rate (CAGR) of 4.3%. The upward trend in this historical duration is due to the escalating incidence of respiratory infections, increasing aging demographics, a rise in smoking, a surge in air pollution, and more government initiatives, along with an increase in population indulged in tobacco smoking.
The market for emphysema is predicted to experience consistent expansion in the coming years. It’s set to increase to $5.91 billion by 2029, with a compound annual growth rate (CAGR) of 4.6%. Growth factors throughout the forecast period include higher healthcare expenditure, escalating environmental contamination, growing requirements for diagnostic medical tools, increasing vehicle congestion, and a surge in demand for less invasive treatments. Significant trends during the forecast period consist of novel inhalation devices, strategic alliances, individualized treatment, telehealth, progress in inhalation therapies, and medical advancements.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21956&type=smp
What are the Fundamental Drivers and Innovations Shaping the Emphysema Market?
The upward trend in respiratory infections is anticipated to fuel the expansion of the emphysema market. These infections impact the respiratory system, involving the sinuses, throat, airways and lungs. The rise in respiratory infections can be attributed to factors such as pollution, climate change, antimicrobial resistance, urbanization, and evolving pathogens. They hasten the progression of emphysema by triggering inflammation, damaging tissue, and intensifying airway obstruction, thereby aggravating lung function. For instance, the Centers for Disease Control and Prevention, a United States government agency, reported that in November 2024, there were 9,633 TB cases reported in the year 2023, a 15.6% increase from 8,332 cases in 2022, and the incidence rate surged by 15.0% from 2.5 to 2.9 per 100,000 individuals. Hence, the escalating frequency of respiratory infections is helping the emphysema market to grow.
How Is the Emphysema Market Segmented?
The emphysemamarket covered in this report is segmented –
1) By Type: Centrilobular; Panlobular
2) By Treatment: Medication; Therapy; Surgery; Other Treatments
3) By Diagnosis: Imaging Test; Lung Function Test; Other Diagnosis
4) By Complications: Chest Infections; Collapsed Lung; Heart Problems; Lungs Hole; Other Complications
5) By End-user: Hospitals And Clinics; Surgical Center; Other End-users
Subsegments:
1) By Centrilobular: Mild Centrilobular Emphysema; Moderate Centrilobular Emphysema; Severe Centrilobular Emphysema
2) By Panlobular: Mild Panlobular Emphysema; Moderate Panlobular Emphysema; Severe Panlobular Emphysema
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=21956&type=smp
Which Regions Are Driving the Next Phase of the Emphysema Market Growth?
North America was the largest region in the emphysema market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the emphysema market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Key Trends Are Shaping the Future of the Emphysema Market?
Leading firms in the emphysema market are prioritizing medical advancements, such as the application of inhaled dual inhibitors of phosphodiesterase 3 and 4. These modern treatments enhance lung functionality, mitigate inflammation, and upgrade overall disease management, thereby promoting superior respiratory health and life quality. An inhaled dual inhibitor of phosphodiesterase 3 and 4 is a medication designed to target and obstruct both phosphodiesterase enzymes found in the lungs. The result is a relaxation of the airways and reduced inflammation, which enhances breathing in conditions akin to chronic obstructive pulmonary disease. For instance, in June 2024, Verona Pharma plc, a pharmaceutical corporation based in the UK, introduced Ohtuvayre (ensifentrine), the inaugural inhaled dual PDE3 and PDE4 inhibitor approved by the Food and Drug Administration, a federal agency in the US, for the maintenance therapy of chronic obstructive pulmonary diseases like emphysema. This marked the launch of the first innovative inhaled therapy in over two decades. The drug, which synergizes bronchodilation and anti-inflammatory effects, will be accessible via specialty pharmacies.
View the full report here:
https://www.thebusinessresearchcompany.com/report/emphysema-global-market-report
How Is the Emphysema Market Defined and What Are Its Core Parameters?
Emphysema is a chronic lung disease that damages the air sacs (alveoli) in the lungs, leading to difficulty in breathing. It is a form of chronic obstructive pulmonary disease (COPD) and is primarily caused by smoking or long-term exposure to air pollutants. As the alveoli become weakened and lose their elasticity, air gets trapped, making it harder for the lungs to expel carbon dioxide and take in fresh oxygen. This results in shortness of breath, chronic cough, and reduced lung function over time.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21956
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
